5th Circuit Affirms Texas’ FDA Defense Law In Abilify Withdrawal Suit

(October 30, 2018, 1:16 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on Oct. 29 affirmed that a pro se plaintiff’s withdrawal injury claim from the atypical antipsychotic Abilify is barred by a...

To view the full article, register now.